Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: selective serotonin reuptake inhibitor Clear all

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Anaheim, California • San Diego, California + 9 more

Conditions: Anxiety Disorders
Interventions: sertraline; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 8 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Depression
Interventions: Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT); Drug · Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Bipolar Depression
Interventions: Escitalopram, Celecoxib, Placebo; Drug
Lead sponsor: Loyola University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: PTSD, Alcohol Use Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo oral tablet; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 90 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: RO4917523, escitalopram, methylphenidate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Spinal Cord Injury
Interventions: Venlafaxine HCl, Placebo; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Stroke, Visual Field Loss
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Bogachan Sahin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depressive Disorder (MDD)
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more

Conditions: Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions: Lurasidone, FDA Approved antidepressant treatment; Drug
Lead sponsor: George West Mental Health Foundation d/b/a Skyland Trail; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alzheimer Disease
Interventions: Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Borderline Personality Disorder
Interventions: Fluoxetine, Dialectical Behavior Therapy, Supportive psychotherapy; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Irritable Bowel Syndrome
Interventions: Citalopram, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Generalized Anxiety Disorder, Panic Disorder
Interventions: Niravam, SSRI/SNRI; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Irvine, California • La Habra, California • Redlands, California + 19 more

Conditions: Ejaculation
Interventions: Treatment sequence 2, Treatment sequence 1; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Anniston, Alabama • Tempe, Arizona • Costa Mesa, California + 3 more

Conditions: Glioma of Brain, Glioma
Interventions: Escitalopram Oral Capsules; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Anxiety Disorder of Adolescence
Interventions: Sertraline, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 16 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Panic Disorder
Interventions: Paroxetine, Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obsessive-Compulsive Disorder
Interventions: selective serotonin reuptake inhibitor; Drug
Lead sponsor: University of Sao Paulo; Other
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Aticaprant; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 87
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 70 more

Conditions: Major Depressive Disorder
Interventions: Creatine, Placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain, Total Knee Replacement, Total Hip Replacement
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.

The ISLAND Study: InSuLa Assessed Needs for Depression

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

Mechanisms of Antidepressant Non-Response in Late-Life Depression

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

Fluoxetine for Visual Recovery After Ischemic Stroke

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

Citalopram in Irritable Bowel Syndrome

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

A Study Utilizing Escitalopram in Glioma Patients

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

Predicting Treatment Response in Patients With OCD

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Predicting, Understanding and Speeding Recovery After TKA